Health & Medical · Week of Nov 2, 2026
Splits, divestitures and stake deals: the week in health releases
Restructuring and dealmaking led the week, from CVS Health's planned split to divestitures and investments at Vantive, Waters and Zylox-Tonbridge.
Corporate restructuring was the main thread this week. CVS Health said it intends to separate into two publicly traded companies, with completion expected in the first half of 2028. Vantive agreed to sell most of its hemodialysis business to Rockwell Medical, saying the move sharpens its focus on home dialysis and critical care. Zylox-Tonbridge and GL Capital announced a joint investment of about HK$1.482 billion in LifeTech Scientific, and Zylox-Tonbridge said it intends to pursue a potential merger. Waters Corporation paired its quarterly results with the acquisition of MOBILion Systems.
Earnings and sales updates made up much of the rest. Waters raised its full-year 2026 guidance, while Trulieve reported lower revenue but a return to net income and said it received final DEA registrations for state licensed medical marijuana dispensaries. Orthocell reported its strongest U.S. month for Remplir sales since launch. Illumina was selected to sequence about 450,000 people for a Singapore precision medicine study, and Elanco released survey data on U.S. pet health spending.
Waters Corporation
Waters Corporation (NYSE: WAT) Reports Third Quarter 2026 Financial Results
Waters Corporation reported third quarter 2026 revenue of $1.767 billion and adjusted EPS of $4.10, raised full-year guidance to $6.479 billion to $6.497 billion in revenue, and announced it has acquired MOBILion Systems, Inc., a developer of SLIM ion mobility separation technology. GAAP diluted EPS fell to $0.82 from $2.50, which the company attributes to acquisition-related and restructuring charges, while organic revenue grew 9% as reported.
Trulieve Cannabis Corp.
Trulieve Reports Third Quarter 2026 Results
Trulieve reported third quarter 2026 revenue of $230 million, down 20% from $288 million a year earlier, with net income attributable to common shareholders of $1 million versus a $27 million loss and adjusted EBITDA of $89 million. The company says it received final DEA registrations for state licensed medical marijuana dispensaries under the Controlled Substances Act and repaid $65 million of mortgage notes ahead of their 2028 maturity.
CVS Health
CVS Health Announces Intent to Create Two Distinct Leaders in Healthcare
CVS Health said it intends to separate into two independent public companies: one comprising Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health led by David Joyner, and CVS Pharmacy, with approximately 9,000 pharmacies and MinuteClinic, led by Prem Shah. The company expects completion in the first half of 2028, subject to conditions including final board approval and confirmation of tax-free treatment.
Elanco Animal Health
October Consumer Research Confirms Pet Health Remains Non-Negotiable Household Priority
Elanco Animal Health released an October 16 to 21, 2026 survey of 2,018 U.S. adults in which 93% of pet owners said they maintained or increased pet spending and 7 percent of consumers said they would cut pet health spending under economic pressure. The survey, commissioned by Elanco, also found 38% of pet owners have shifted medication purchasing outside the clinic in the past year or two.
VANTIVE US HEALTHCARE LLC
Vantive Announces Agreement to Divest Majority of Hemodialysis Assets and Associated Operations to Rockwell Medical
Vantive agreed to divest the majority of its hemodialysis business, including concentrates, HD monitors, water treatment systems and its Medolla, Italy manufacturing facility, to Rockwell Medical, with closing expected in mid-2027. Its dialyzer portfolio, including the Theranova dialyzer, is excluded, and Vantive says the deal sharpens its focus on home dialysis and critical care.
Illumina, Inc.
Illumina selected to help bring precision medicine into everyday healthcare in Singapore
Illumina said it was selected through an international competitive tender to provide whole-genome sequencing for the SG-INSIGHT study under Phase III of Singapore's National Precision Medicine programme. The study is expected to include approximately 450,000 individuals, about one in 10 Singapore residents, and aims to support the introduction of genetic screening in the public healthcare system.
Orthocell Limited
Orthocell Achieves Strongest Month of U.S. Remplir™ Sales Since Launch
Orthocell reported U.S. sales of 92 Remplir units in October 2026, generating AU$279,000 in revenue, an 84% uplift on average monthly sales of 50 units in Q1 FY27. The company attributes the increase to surgeon adoption, repeat use and expanded hospital access, and says it is expanding manufacturing capacity for the collagen nerve wrap.
ZYLOX-TONBRIDGE
Zylox-Tonbridge and GL Capital Announce Strategic Investment in LifeTech Scientific to Build a Leading Vascular and Structural Heart Intervention Platform
Zylox-Tonbridge and GL Capital will jointly invest approximately HK$1.482 billion in LifeTech Scientific for about 16.7% of its enlarged share capital, making their vehicle LifeTech's largest single shareholder, while GL Capital subscribes for 39.8 million new Zylox-Tonbridge shares at HK$22 each. Zylox-Tonbridge says it intends to pursue a potential merger with LifeTech, though no completion date was given.
This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not News Today Lines reporting.